Global Anthrax Vaccines Market Size By Product Type (Cell-Free PA Vaccines, Live Cells), By Application (Animal Use, Human Use), By End-User (Hospital Pharmacy, Retail pharmacy), By Geographic Scope And Forecast

Anthrax Vaccines Market Size And Forecast

Anthrax Vaccines Market size is growing at a moderate pace with substantial growth rates over the last few years and is estimated that the market will grow significantly in the forecasted period i.e. 2023 to 2030.

Because of the rising prevalence of the disease, the global market for anthrax vaccinations is rapidly growing. The market for anthrax vaccinations is driven by the increased consumption of undercooked or raw meat from diseased animals. Increased industrial or manufacturing processing of contaminated commodities like skins and hair wool will also help to grow the market. The Global Anthrax Vaccines Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Anthrax Vaccines Market Definition

Anthrax is a dangerous infection caused by the bacteria Bacillus anthracis. There is a vaccination that can help avoid it. This vaccination, however, is not normally available to the general population. It is only indicated for persons who are at a high risk of contracting B. anthracis or who have already been exposed to it. Anthrax is a serious infectious disease caused by the spores of Bacillus anthracis, a gram-positive bacterium. The lungs, intestines, skin, and injectables are the four main routes of infection. Both humans and animals are susceptible to anthrax, particularly ruminants like cattle, sheep, goats, and horses. It is difficult to spread from one individual to another.

Anthrax symptoms and signs differ based on the type of infection. The symptoms of cutaneous anthrax, gastrointestinal anthrax, inhalation anthrax, and injectable anthrax differ. The most common signs and symptoms of gastrointestinal anthrax include nausea, abdominal pain, lack of appetite, vomiting, fever, bloody diarrhea, swelling neck, headache, and difficulty swallowing. Inhalation anthrax causes shortness of breath, blood in the cough, uncomfortable swallowing, minor chest discomfort, and nausea. The most common indications and symptoms of injectable anthrax are multiple organ failure, meningitis, and redness around the injection site.

Currently, the primary approaches in the diagnosis of anthrax available worldwide rely on the presence or absence of antibodies or toxins in a patient’s blood sample. Furthermore, healthcare professionals advised using direct testing to diagnose the presence of Bacillus anthracis. Anthrax vaccinations are available in both cell-free and live forms. The main reason for anthrax immunization is the danger of infection through inhalation. An acellular vaccine (anthrax vaccine adsorbed or AVA), which contains anthrax toxin components and results in protective immunity after 3 to 6 doses, is used as a pre-exposure vaccine. Anthrax vaccine precipitated (AVP) is given in three doses at prime vaccination, with a booster dose 6 months later. A booster dose is required once every 12 months to elicit and sustain protective immunity.

Current anthrax vaccinations have a high level of local and overall reactogenicity (erythema, induration, soreness, fever). About 1% of immunizations have serious side effects. Recombinant live vaccines and recombinant sub-unit vaccines are the two new second-generation vaccines that are currently in development. Anthrax Vaccine Adsorbed (AVA) or BioThraxTM, the only licensed anthrax vaccine, is recommended for active vaccination for the prevention of disease caused by Bacillus anthracis in those aged 18 to 65 who are at a high risk of exposure. Emergent BioDefense Operations Lansing Inc. in Lansing, Michigan, has been licensed to manufacture the vaccine since 1970. Multiple companies are working on next-generation anthrax vaccinations.

Global Anthrax Vaccines Market Overview

Because of the rising occurrence of anthrax, the Anthrax Vaccines Market is fast growing. A major driver of the global market is the rise in popularity of eating raw and undercooked meat from infected animals. Furthermore, a large increase in the commercial and industrial processing of contaminated animal commodities such as hair wool, and hide boosted the market growth. Anthrax is most commonly seen in wild wildlife and livestock. The number of farms is growing as animal husbandry becomes more popular around the world. Working on farms puts people in close proximity to animals, putting them at risk of contracting anthrax. This element operates as the market’s primary driving force.

The low percentage of voluntarily screening for anthrax disease, on the other hand, could be a major impediment to the Anthrax Vaccines Market. Furthermore, in places like Africa, a lack of understanding regarding anthrax diagnostic tests makes it difficult for companies to reach out directly to their clients, stifling market growth. Factors such as the rising prevalence of anthrax and the expanding consumption of undercooked or raw meat are mostly to blame for the market’s expansion. It may be possible to avoid it in both animals and humans by improving diagnosis, surveillance, and outbreak response. The disease has a high prevalence rate, and the risk and severity of infection make it one of the top priorities for preventive healthcare organizations.

Anthrax has been found in animals as a result of infected meat. Although the consumption patterns in chicken, beef, and pork are substantially different, they all raise the risk of anthrax. As a result of the foregoing, the Anthrax Vaccines Market is likely to expand over the forecast period. Although the market is dominated by a few players and is likely to develop over the forecast period, factors such as a lack of awareness regarding diagnostic and screening tests and the anthrax vaccine’s exorbitant cost may hinder market expansion.

Global Anthrax Vaccines Market Segmentation Analysis

The Global Anthrax Vaccines Market is segmented based on Product Type, Application, End-User, And Geography.

Anthrax Vaccines Market, By Product Type

• Cell-Free PA Vaccineso Anthrax Vaccine Adsorbed (AVA)o Anthrax Vaccine Precipitated (AVP)• Live Cells

Based on the Product Type, the market is bifurcated into Cell-Free PA Vaccines and Live Cells. Cell-Free PA Vaccines are expected to hold the largest market share in the coming years.

Anthrax Vaccines Market, By Application

• Animal Use• Human Use

Based on Application, the market is bifurcated into Animal Use And Human Use. The animal use anthrax vaccination segment is expected to dominate the market. Anthrax is an epizootic disease that spreads from animals to humans and appears in sensitive animals, both wild and domesticated, on a regular basis. Anthrax is acute septicemia with a high fatality rate in herbivore animals such as cattle, sheep, goats, camels, and antelopes. It is generally accompanied by hemorrhagic lymphadenitis. In dogs, pigs, and horses, however, it is a less severe but possibly lethal condition.

Anthrax Vaccines Market, By End-User

• Hospital Pharmacy• Retail pharmacy• Others

Based on End-User, the market is bifurcated into Hospital Pharmacy, Retail pharmacy, and Others. Hospital pharmacies dominated the market. Hospitals serve as a key immunization venue, which explains why anthrax vaccine sales are so high there. Anthrax vaccines are, additionally, routinely administered to patients in hospitals.

Anthrax Vaccines Market, By Geography

• North America• Europe• Asia Pacific• Rest of the world

On the basis of Geography, the Global Anthrax Vaccines Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. The largest share in the market will be dominated by North America owing to the growing number of anthrax patients.

Key Players

The “Global Anthrax Vaccines Market” study report will provide a valuable insight with an emphasis on global market including some of the major players such as Zoetis Inc., Emergent Bio-Solutions, Merck & Co. Inc., Colorado Serum, PharmaAthene Inc., Vecol, Biogenesis Bago Inc., Porton Biopharma Inc., Merial, and Intervac.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share and market ranking analysis of the above-mentioned players globally.

Key Developments

• In August 2020, Anthim (obiltoxaximab for injection), a monoclonal antibody (mAb) anthrax antitoxin, developed by Elusys Therapeutics Inc. (Elusys), obtained approval from Health Canada for the treatment of inhalation anthrax and can be used to treat post-exposure prophylaxis in both adults and children.

• In August 2020, Dr. Jamie Benn Felix and the Cook Wildlife Lab team from Texas A&M University College of Veterinary Medicine & Biomedical Sciences performed pilot research for the first oral anthrax vaccine for livestock (CVMBS).

Report Scope

Top Trending Reports

Research Methodology of Market Research

To know more about the Research Methodology and other aspects of the research study, kindly get in touch with our .

Reasons to Purchase this Report

• Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors• Provision of market value (USD Billion) data for each segment and sub-segment• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled• Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players• The current as well as the future market outlook of the industry with respect to recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions• Includes in-depth analysis of the market of various perspectives through Porter’s five forces analysis• Provides insight into the market through Value Chain• Market dynamics scenario, along with growth opportunities of the market in the years to come• 6-month post-sales analyst support

Customization of the Report

• In case of any please connect with our sales team, who will ensure that your requirements are met.